SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is generating buzz as its community anticipates the upcoming 4/20 cultural event, rallying around its mission to support global cannabis legalization and integrate real-world utility while proclaiming itself "like Bitcoin but way higher."

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.

Harrow Inc

Harrow Health Inc

Harrow Health is trending due to reaffirmed FY25 outlook and robust VEVYE script trends, bolstered by CVS Caremark Tier 1 formulary status. The community actively anticipates a potential short squeeze and accelerated growth, further fueled by a Deloitte audit upgrade signaling big-cap ambitions within the ophthalmic sector.

Spire Global, Inc. collects space-based data using a proprietary constellation of low earth multi-use receiver nanosatellites. Its software analytics generate proprietary data, insights and predictive analytics for its customers through a subscription model. The company was founded by Peter Platzer in August 2012 and is headquartered in Vienna, VA.

Spire Global Inc - Ordinary Shares - Class A

Spire Global is generating significant buzz following its selection for the Missile Defense Agency's $151 billion SHIELD IDIQ contract. This, combined with the recent completion of its maritime business sale that eliminated all outstanding debt, is fueling community discussions about the company's strengthened financial position and growth prospects.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMA Biologics is actively discussed following its recent Q3 earnings report, which highlighted a revenue beat and raised guidance but resulted in a puzzling stock dip, intensified by a prior FDA alert concerning certain product lots. The community views this as a significant undervaluation, with many anticipating a strong rebound driven by operational efficiencies, future catalysts, and persistent speculation of a potential takeover.

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.

Abeona Therapeutics Inc

Abeona Therapeutics is trending as community discussion focuses on the recent commercial launch and ramp-up of its gene therapy, ZEVASKYN, highlighted by an effective J-code and expanding treatment capacity. Despite strong institutional ownership and analyst price targets, the stock is seen by many as deeply undervalued, trading near its cash value, while also attracting significant short interest, with investors anticipating sustained revenue growth and pipeline catalysts.

Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.

Niagen Bioscience Inc.

Niagen Bioscience is gaining significant attention as the market anticipates pivotal NOPARK Parkinson's trial results, which are further underscored by a new international licensing agreement and recent Long COVID study findings. The community is also closely watching the expansion of its Niagen Plus IV and injectable therapies, coupled with strategic partnerships like Herbalife, while high short interest fuels speculation of a potential squeeze.

Nutanix, Inc. engages in the provision of a cloud platform leveraging web-scale engineering and consumer-grade design. It operates through the following geographic segments: United States, Europe, the Middle East, Africa, Asia Pacific, and Other Americas. The firm also provides software solutions and cloud services to customers' enterprise infrastructure. The company was founded by Dheeraj Pandey, Ajeet Singh, and Mohit Aron in 2009 and is headquartered in San Jose, CA.

Nutanix Inc - Ordinary Shares - Class A

Nutanix Inc 

Nutanix is trending as the company announced a significant accelerated share repurchase program, signaling confidence and prompting a rebound after a recent downturn. The community is actively discussing whether this buyback, coupled with its strategic position in hybrid cloud and enterprise AI against competitors like Broadcom/VMware, can sustain a recovery from recent declines.

USDX (Website: usdx.money | Twitter: @StablesLabs) is a synthetic USD stablecoin designed to provide stability without relying on traditional banking infrastructure. Backed by delta-neutral positions across multiple exchanges, USDX seamlessly bridges the gap between DeFi, CeFi, and TradFi. It enables DeFi users to access traditional delta-neutral strategies executed in CeFi platforms. As a crypto-native stablecoin, USDX offers a scalable, censorship-resistant, and highly stable solution for users looking to navigate the world of decentralized finance with confidence.

USDX Stablecoin

USDX Stablecoin is trending after its significant de-pegging below $0.45, an event driven by the Balancer hack and the collapse of Stream Finance and Elixirs, which has intensified community debate over the fragility of DeFi stablecoins.

FMC Corp. is an agricultural sciences company, which engages in the provision of solutions to growers and development of pipeline in crop protection, plant health, agriculture, pest control, and turf management. It offers insect control products under the Rynaxypyr and Cyazypyr brands, herbicides under the Authority, Boral, Centium, Command, and Gamit brands, insecticides under the Talstar and Hero brands, flutriafol-based fungicides, and bionematicides under the Quartzo and Presence brands. The company was founded by John Bean in 1883 and is headquartered in Philadelphia, PA.

FMC Corp.

FMC Corporation is trending after reporting a significant Q4 earnings and revenue miss, paired with a substantial dividend cut and the initiation of a strategic review including a potential sale, leading to widespread community debate over its high debt and future viability as an oversold value play or a deeper value trap.

Green Satoshi Token

Green Satoshi Token (GSTSOL) is garnering significant attention amid calls for an impending altcoin season, with the community actively discussing increasing volume and technical signals that suggest an imminent, substantial price movement.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Liberty Broadband (NASDAQ:LBRDK) Shares Gap Up - Here's What Happened

Liberty Broadband (NASDAQ:LBRDK) Shares Gap Up - Here's Why...

Liberty Broadband (NASDAQ:LBRDA) Shares Gap Up - What's Next?

Liberty Broadband (NASDAQ:LBRDA) Shares Gap Up - What's Next...

Liberty Broadband (NASDAQ:LBRDK) Sets New 12-Month Low - Should You Sell?

Liberty Broadband (NASDAQ:LBRDK) Reaches New 12-Month Low - Time to Sell...

Liberty Broadband (NASDAQ:LBRDA) Hits New 12-Month Low - What's Next?

Liberty Broadband (NASDAQ:LBRDA) Hits New 52-Week Low - Time to Sell...

Liberty Broadband (NASDAQ:LBRDK) Hits New 12-Month Low - Should You Sell?

Liberty Broadband (NASDAQ:LBRDK) Sets New 12-Month Low - What's Next...

Liberty Broadband (NASDAQ:LBRDA) Reaches New 1-Year Low - Time to Sell?

Liberty Broadband (NASDAQ:LBRDA) Reaches New 52-Week Low - Here's What Happened...

Liberty Broadband Corp Implements A Sell Strategy: Offloads $100.00M In Charter Communications Stock

Liberty Broadband (NASDAQ:LBRDK) Stock Passes Below Fifty Day Moving Average - Should You Sell?

Liberty Broadband (NASDAQ:LBRDK) Share Price Crosses Below 50-Day Moving Average - What's Next...

Liberty Broadband (NASDAQ:LBRDA) Sees Large Volume Increase - Here's Why

Liberty Broadband (NASDAQ:LBRDA) Sees Strong Trading Volume - Here's What Happened...

Liberty Broadband (NASDAQ:LBRDA) Share Price Passes Below Fifty Day Moving Average - Here's Why

Liberty Broadband (NASDAQ:LBRDA) Share Price Passes Below 50 Day Moving Average - Time to Sell...

Liberty Broadband Corp. operates as a holding company, which engages in the cable, broadband, and mobile location technology businesses. It operates through the following segments: GCI Holdings, Charter, and Corporate and Other. The GCI Holdings segment provides data, wireless, video, voice, and managed services to residential, businesses, governmental entities, and educational and medical institutions primarily in Alaska. The Charter segment provides cable services in the United States, offering entertainment, information, and communications solutions to residential and commercial customers. The company was founded on March 28, 1991 and is headquartered in Englewood, CO.

Liberty Broadband Corp - Ordinary Shares - Series A

Up 5%

Down 5%

Markets are hovering near key levels, making the next 5% move especially important for sentiment. A breakout higher could reinforce the bull case, while a 5% drop may signal rising risk and tighter conditions. Which comes first?

What will be the S&amp;P 500’s next 5% move?

Stocktwits

What will be the S&P 500’s next 5% move?

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '25	$1.12	$1.75	55.83%	BEAT
Q4 '24	$2.84	$2.04	-28.07%	MISSED
Q3 '24	$2.11	$0.99	-53.10%	MISSED
Q2 '24	$1.71	$1.36	-20.61%	MISSED
Q1 '24	$1.95	$1.69	-13.53%	MISSED

LBRDA
Liberty Broadband Corp - Ordinary Shares - Series A

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '25

Historical Earnings

Latest LBRDA News

LBRDALiberty Broadband Corp - Ordinary Shares - Series A